IDEAYA Biosciences, Inc. Common Stock IDYA
Analyst Ratings
- Consensus
- Buy — 14 Buy · 1 Hold · 0 Sell (15 analysts)
- Avg. Price Target
- $52.86 (+36.0% upside)
Key Stats
- Today's Range
- $37.84 – $39.30
- 50-Day Range
- $26.81 – $40.58
- 52-Week Range
- $21.33 – $40.58
- Volume
- 932K shs
- Average Volume
- 725K shs
- Market Cap
- $3.66 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 3.05
- Price / Sales
- 15.63
Short Interest
- Short Interest
- 0.14%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $234.13 million
- Net Income
- $-175,020,000
- Net Margin
- -74.75%
- Return on Equity
- -14.60%
- Debt-to-Equity
- —
About IDEAYA Biosciences, Inc. Common Stock
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Related Stocks
Compare head-to-head: IDYA vs LLY·IDYA vs JNJ·IDYA vs ABBV·IDYA vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.